Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC

PFS Clinical Trial

Official title:
Phase II Randomized Trial of Carboplatin/Cisplatin+Pemetrexed+PD-1 Inhibitor+/- Bevacizumab in Stage IV Non-squamous NSCLC

Status Recruiting

Clinical Trial Summary

In recent years, immunotherapy has emerged as a form of treatment that can lead to robust responses in a subset of patients. PD-1 inhibitor plus chemotherapy showed prolonged survival in NSCLC by the study of KEYNOTE 024, KEYNOTE 189 etc. Thus, this study combines immunotherapeutic agent PD-1 inhibitor with an ant-angiogenic agent, bevacizumab, and double platinum therapy (carboplatin/cisplatin and pemetrexed).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05267366
Study type	Interventional
Source	Qingdao Central Hospital
Contact
Status	Recruiting
Phase	Phase 2
Start date	February 1, 2022
Completion date	July 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04425187` - Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC	Phase 2
Not yet recruiting	`NCT05638984` - Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT05267288` - Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT02629718` - Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer	Phase 3
Recruiting	`NCT04520035` - Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell	Phase 2